Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05855083 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
A Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies, sponsored by Omeros Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 16
- Study locations
NCT05855083 is a Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies that is actively recruiting participants, run by Omeros Corporation. The registered enrollment target is 18 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 16 study locations across 8 states.
The verdict
NCT05855083, a Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies, is actively recruiting participants, sponsored by Omeros Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Conditions Studied
Interventions
- DRUG Biological: narsoplimab
Study Locations (16)
Other
- Omeros Investigational Site - Halle
- Omeros Investigational Site - Hanover
- Omeros Investigational Site - Haifa
- Omeros Investigational Site - Jerusalem
- Omeros Investigational Site - Ramat Gan
- Omeros Investigational Site - Tel Aviv
- Omeros Investigational Site - Utrecht
- Omeros Investigational Site - Pamplona
New York
- Omeros Investigational Site - New York
- Omeros Investigational Site - Valhalla
California
- Omeros Investigational Site - San Diego
Florida
- Omeros Investigational Site - Gainesville
Massachusetts
- Omeros Investigational Site - Boston
Missouri
- Omeros Investigational Site - St Louis
Texas
- Omeros Investigational Site - Houston
Washington
- Omeros Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05855083
The ClinicalTrials.gov registry entry for NCT05855083 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Biological: narsoplimab is the first listed.
NCT05855083 reports 16 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT05855083 about?
NCT05855083 is a clinical study titled "Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA". The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
What is the current status of trial NCT05855083?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2023-05-01. Estimated completion is 2025-12.
What conditions does trial NCT05855083 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation, Thrombotic Microangiopathies.
What interventions are being tested in trial NCT05855083?
The interventions under investigation include: Biological: narsoplimab (DRUG).
Who is sponsoring clinical trial NCT05855083?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05855083 being conducted?
This trial has 16 study locations across California, Florida, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
RECRUITING · Phase 2
-
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
RECRUITING · Phase 2
-
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
-
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
COMPLETED · Phase 2
-
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
COMPLETED · Phase 2
-
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 1
Explore more on PlainTrial
Hematopoietic Stem Cell Transplantation
All registered trials for this condition
Thrombotic Microangiopathies
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.